#bcmsl

MSL EDUCATION - IMMUNOTHERAPY IO, immuno-oncology and/or immunotherapy has been a hot topic for the past many years. The amount if MSL jobs in this space are on the rise as the same drugs are approved for more and more tumor streams. Upskill yourself on IO and be able to move into a highly exciting career. https://lnkd.in/gG3KeM9 #MSL #MSLS #medicalaffairs #BCMSL #BoardCertifiedMSL #TheMSLcommunity Msl society #FSTP #medicalscienceliaison #health #healthcare #Phdlife #phd ACMA #pharmd #MSLsalary #pharmacist #phd #phdlife #io #immunooncology #immunotherapy https://www.instagram.com/p/CQW3z8Nj4D2/?utm_medium=tumblr

FDA APPROVAL - 1st BCMA CART The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy. Abecma is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. Each dose of Abecma is a customized treatment created by using a patient’s own T-cells, which are a type of white blood cell, to help fight the myeloma. The patient’s T-cells are collected and genetically modified to include a new gene that facilitates targeting and killing myeloma cells. Once the cells are modified, they are infused back into the patient. https://lnkd.in/e6DURz9 #MSL #MSLS #medicalaffairs #BCMSL #BoardCertifiedMSL #TheMSLcommunity Msl society #FSTP #medicalscienceliaison #health #healthcare #Phdlife #phd #pharmd #MSLsalary #pharmacist #phd #phdlife https://www.instagram.com/p/CPkoGB0jRiP/?utm_medium=tumblr